- Home
- ABSI vs DBVT Comparison
ABSI vs DBVT Comparison
Compare ABSI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- DBVT
- Stock Information
- Founded
- ABSI 2011
- DBVT 2002
- Country
- ABSI United States
- DBVT France
- Employees
- ABSI N/A
- DBVT N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABSI Health Care
- DBVT Health Care
- Exchange
- ABSI Nasdaq
- DBVT Nasdaq
- Market Cap
- ABSI 505.4M
- DBVT 464.0M
- IPO Year
- ABSI 2021
- DBVT N/A
- Fundamental
- Price
- ABSI $3.35
- DBVT $14.15
- Analyst Decision
- ABSI Strong Buy
- DBVT Buy
- Analyst Count
- ABSI 6
- DBVT 5
- Target Price
- ABSI $7.98
- DBVT $15.85
- AVG Volume (30 Days)
- ABSI 5.2M
- DBVT 162.4K
- Earning Date
- ABSI 11-12-2025
- DBVT 10-28-2025
- Dividend Yield
- ABSI N/A
- DBVT N/A
- EPS Growth
- ABSI N/A
- DBVT N/A
- EPS
- ABSI N/A
- DBVT N/A
- Revenue
- ABSI $4,138,000.00
- DBVT $5,502,000.00
- Revenue This Year
- ABSI $40.12
- DBVT $1,743.46
- Revenue Next Year
- ABSI $331.37
- DBVT $1,045.66
- P/E Ratio
- ABSI N/A
- DBVT N/A
- Revenue Growth
- ABSI 27.32
- DBVT N/A
- 52 Week Low
- ABSI $2.01
- DBVT $2.21
- 52 Week High
- ABSI $6.33
- DBVT $18.00
- Technical
- Relative Strength Index (RSI)
- ABSI 39.43
- DBVT 49.06
- Support Level
- ABSI $4.15
- DBVT $13.70
- Resistance Level
- ABSI $4.38
- DBVT $15.34
- Average True Range (ATR)
- ABSI 0.28
- DBVT 1.11
- MACD
- ABSI -0.16
- DBVT -0.38
- Stochastic Oscillator
- ABSI 9.11
- DBVT 22.74
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.